J Antimicrob Chemother 2004,54(6):1134–1138 PubMedCrossRef 33 Wu

J Antimicrob Chemother 2004,54(6):1134–1138.learn more PubMedCrossRef 33. Wuthiekanun V, Cheng AC, Chierakul W, Amornchai P, Limmathurotsakul D, Chaowagul

W, Simpson AJ, Short JM, Wongsuvan G, Maharjan B, White NJ, Peacock SJ: Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother 2005,55(6):1029–1031.PubMedCrossRef 34. Ho PL, Cheung TK, Yam WC, Yuen KY: Characterization find more of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother 2002,50(5):723–726.PubMedCrossRef 35. Cheung TK, Ho PL, Woo PC, Yuen KY, Chau PY: Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei. Antimicrob Agents Chemother 2002,46(4):1132–1135.PubMedCrossRef 36. Niumsup P, Wuthiekanun V: Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J Antimicrob Chemother 2002,50(4):445–455.PubMedCrossRef 37. Wuthiekanun V, Peacock U0126 cell line SJ: Management of melioidosis. Expert Rev Anti Infect Ther 2006,4(3):445–455.PubMedCrossRef 38. Peacock SJ, Schweizer HP, Dance DA, Smith TL, Gee JE, Wuthiekanun V, DeShazer D,

Steinmetz I, Tan P, Currie BJ: Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis 2008,14(7):e2.PubMedCrossRef 39. Cheng AC, McBryde ES, Wuthiekanun V, Chierakul W, Amornchai P, Day NP, White NJ, Peacock SJ: Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. Antimicrob Agents Chemother Methocarbamol 2009,53(10):4193–4199.PubMedCrossRef 40. Burtnick MN, Brett PJ, Woods DE: Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol 2002,184(3):849–852.PubMedCrossRef 41. Ribot WJ, Ulrich RL: The animal pathogen-like type III secretion system is required for the intracellular survival of Burkholderia mallei within J774.2 macrophages. Infect Immun 2006,74(7):4349–4353.PubMedCrossRef 42. Kenny DJ, Russell P, Rogers D, Eley SM, Titball RW: In vitro susceptibilities of Burkholderia mallei in comparison to those of other

pathogenic Burkholderia spp. Antimicrob Agents Chemother 1999,43(11):2773–2775.PubMed 43. Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, Chen D, Lipscomb L, Kim HS, Mrazek J, Nierman WC, Deshazer D: Type VI secretion is a major virulence determinant in Burkholderia mallei. Mol Microbiol 2007,64(6):1466–1485.PubMedCrossRef 44. Shalom G, Shaw JG, Thomas MS: In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages. Microbiology 2007,153(Pt 8):2689–2699.PubMedCrossRef 45. Warawa J, Woods DE: Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett 2005,242(1):101–108.PubMedCrossRef 46.

Comments are closed.